Sangui Bio
Sangui Bio is a biotechnology company founded in 2015, specializing in blood analysis, biomarker discovery, and diagnostics. Located at the Kolling Institute in Sydney, it leverages clinical networks and advanced microsampling technologies to develop innovative blood-based diagnostic tools, particularly for cancer and other diseases. The company's mission is to enable early disease detection and personalized medicine through novel blood sampling and proteomics methods.
Industries
Nr. of Employees
small (1-50)
Sangui Bio
PO BOX 4054, Royal North Shore Hospital, St Leonards, NSW 2065
Patents
Products
Sequential-extraction microsample proteomics platform
A laboratory platform combining volumetric microsampling, selective washing fractionation, and in‑tip digestion to enable multiplexed extraction (immunoassay + MS) and high-proteome coverage from a single dried blood tip.
Sequential-extraction microsample proteomics platform
A laboratory platform combining volumetric microsampling, selective washing fractionation, and in‑tip digestion to enable multiplexed extraction (immunoassay + MS) and high-proteome coverage from a single dried blood tip.
Services
End-to-end discovery service using volumetric microsampling, selective fractionation, in‑tip digestion, and DIA‑LC‑MS to identify and rank protein biomarkers from clinical cohorts.
Design and operational support for cohort recruitment, at-home fingerprick and stool sample collection, clinical data linkage (e.g., colonoscopy outcomes), and sample handling for biomarker studies.
Stability studies for analytes in dried microsamples and reproducibility assessments (e.g., %CV) across storage conditions and processing workflows to support longitudinal and biobanked samples.
Statistical filtering, ranking (AUC and importance metrics), and machine-learning model training to produce multi-marker diagnostic/predictive panels from proteomic datasets.
PCR-based detection and quantification of circulating tumour DNA mutations adapted for extracts from dried microsamples to complement proteomic biomarker profiles.
End-to-end discovery service using volumetric microsampling, selective fractionation, in‑tip digestion, and DIA‑LC‑MS to identify and rank protein biomarkers from clinical cohorts.
Design and operational support for cohort recruitment, at-home fingerprick and stool sample collection, clinical data linkage (e.g., colonoscopy outcomes), and sample handling for biomarker studies.
Stability studies for analytes in dried microsamples and reproducibility assessments (e.g., %CV) across storage conditions and processing workflows to support longitudinal and biobanked samples.
Statistical filtering, ranking (AUC and importance metrics), and machine-learning model training to produce multi-marker diagnostic/predictive panels from proteomic datasets.
PCR-based detection and quantification of circulating tumour DNA mutations adapted for extracts from dried microsamples to complement proteomic biomarker profiles.
Expertise Areas
- Proteomic biomarker discovery
- Volumetric microsampling and dried blood sample processing
- Sample preparation and fractionation for mass spectrometry
- Clinical cohort study design and at-home longitudinal sampling
Key Technologies
- Volumetric absorptive microsampling (VAMS) / dried blood spot collection
- Selective wash fractionation of microsamples
- In-tip proteolytic digestion
- Data-independent acquisition (DIA) LC‑MS proteomics
News & Updates
A large colorectal polyp study using at-home stool and fingerprick dried blood samples, in partnership with Microba and the Brisbane Colonoscopy Clinic.
The Urgency of Early Diagnosis
Highlighting the importance of early detection in improving survival rates for cancer, especially colorectal cancer.
Working with Leading Experts
Collaborations with top scientists and clinicians on biomarker research and clinical studies.
Research and Publications
Multiple peer-reviewed papers and conference posters on blood biomarker discovery, sample preparation, and proteomics.
A study demonstrating the use of volumetric absorptive microsampling (VAMS) for proteomic analysis of blood in lung cancer patients.
Research on using VAMS and mass spectrometry for early cancer biomarker discovery.
A large colorectal polyp study using at-home stool and fingerprick dried blood samples, in partnership with Microba and the Brisbane Colonoscopy Clinic.
The Urgency of Early Diagnosis
Highlighting the importance of early detection in improving survival rates for cancer, especially colorectal cancer.
Working with Leading Experts
Collaborations with top scientists and clinicians on biomarker research and clinical studies.
Research and Publications
Multiple peer-reviewed papers and conference posters on blood biomarker discovery, sample preparation, and proteomics.
A study demonstrating the use of volumetric absorptive microsampling (VAMS) for proteomic analysis of blood in lung cancer patients.
Research on using VAMS and mass spectrometry for early cancer biomarker discovery.